Why the study?
Can technetium-labeled erythrocyte cardiac imaging detect primary angiosarcoma of the heart?
Can technetium-labeled erythrocyte cardiac imaging detect primary angiosarcoma of the heart?
Technetium-labeled erythrocyte cardiac imaging is suggested as a noninvasive screening test for patients presenting with signs of primary angiosarcoma of the heart.
May support technetium-labeled erythrocyte imaging as noninvasive screening; hypothesis-generating and requires prospective validation.
Patients with primary angiosarcoma of the heart typically have the signs of right-sided congestive heart failure pericardial chest pain and pericardial effusion. The diagnosis of this uncommon tumor can be confirmed by nuclear cardiac scan to demonstrate any filling defect. The authors suggest that patients with this clinical presentation undergo nuclear heart scan as a noninvasive screening test to visualize the cardiac chambers and evaluate cardiac function.
No takes yet. Share an insight, caveat, or question.
Bennett et al. (1982) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: